The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Neuroendocrine tumors (NETs) are neoplasms that arise from cells of the endocrine (hormonal) and nervous systems. Many are benign, while some are malignant. They most commonly occur in the intestine, where they are often called carcinoid tumors, but they are also found in the pancreas, lung and the rest of the body.
Global Neuroendocrine Carcinoma market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Neuroendocrine Carcinoma market research.
The somatostatin analogs segment by treatment type is expected to witness high traction in the coming years.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Neuroendocrine Carcinoma market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Pfizer
Novartis
Chiasma
Ipsen
Abbvie
Valeant
Jubilant
Teva
F.Hoffmann-La Roche
Advanced Accelerator
Mateon
Lexicon
Segment by Type
Chemotherapy
Somatostatin Analogs
Targeted Therapy
Segment by Application
Hospital
Clinics
Oncology Centres
Ambulatory Surgery Centres
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Neuroendocrine Carcinoma report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies' Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Neuroendocrine Carcinoma Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Chemotherapy
1.2.3 Somatostatin Analogs
1.2.4 Targeted Therapy
1.3 Market by Application
1.3.1 Global Neuroendocrine Carcinoma Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Clinics
1.3.4 Oncology Centres
1.3.5 Ambulatory Surgery Centres
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Neuroendocrine Carcinoma Market Perspective (2018-2029)
2.2 Neuroendocrine Carcinoma Growth Trends by Region
2.2.1 Global Neuroendocrine Carcinoma Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Neuroendocrine Carcinoma Historic Market Size by Region (2018-2023)
2.2.3 Neuroendocrine Carcinoma Forecasted Market Size by Region (2024-2029)
2.3 Neuroendocrine Carcinoma Market Dynamics
2.3.1 Neuroendocrine Carcinoma Industry Trends
2.3.2 Neuroendocrine Carcinoma Market Drivers
2.3.3 Neuroendocrine Carcinoma Market Challenges
2.3.4 Neuroendocrine Carcinoma Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Neuroendocrine Carcinoma Players by Revenue
3.1.1 Global Top Neuroendocrine Carcinoma Players by Revenue (2018-2023)
3.1.2 Global Neuroendocrine Carcinoma Revenue Market Share by Players (2018-2023)
3.2 Global Neuroendocrine Carcinoma Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Neuroendocrine Carcinoma Revenue
3.4 Global Neuroendocrine Carcinoma Market Concentration Ratio
3.4.1 Global Neuroendocrine Carcinoma Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Neuroendocrine Carcinoma Revenue in 2022
3.5 Neuroendocrine Carcinoma Key Players Head office and Area Served
3.6 Key Players Neuroendocrine Carcinoma Product Solution and Service
3.7 Date of Enter into Neuroendocrine Carcinoma Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Neuroendocrine Carcinoma Breakdown Data by Type
4.1 Global Neuroendocrine Carcinoma Historic Market Size by Type (2018-2023)
4.2 Global Neuroendocrine Carcinoma Forecasted Market Size by Type (2024-2029)
5 Neuroendocrine Carcinoma Breakdown Data by Application
5.1 Global Neuroendocrine Carcinoma Historic Market Size by Application (2018-2023)
5.2 Global Neuroendocrine Carcinoma Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Neuroendocrine Carcinoma Market Size (2018-2029)
6.2 North America Neuroendocrine Carcinoma Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Neuroendocrine Carcinoma Market Size by Country (2018-2023)
6.4 North America Neuroendocrine Carcinoma Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Neuroendocrine Carcinoma Market Size (2018-2029)
7.2 Europe Neuroendocrine Carcinoma Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Neuroendocrine Carcinoma Market Size by Country (2018-2023)
7.4 Europe Neuroendocrine Carcinoma Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Neuroendocrine Carcinoma Market Size (2018-2029)
8.2 Asia-Pacific Neuroendocrine Carcinoma Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Neuroendocrine Carcinoma Market Size by Region (2018-2023)
8.4 Asia-Pacific Neuroendocrine Carcinoma Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Neuroendocrine Carcinoma Market Size (2018-2029)
9.2 Latin America Neuroendocrine Carcinoma Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Neuroendocrine Carcinoma Market Size by Country (2018-2023)
9.4 Latin America Neuroendocrine Carcinoma Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Neuroendocrine Carcinoma Market Size (2018-2029)
10.2 Middle East & Africa Neuroendocrine Carcinoma Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Neuroendocrine Carcinoma Market Size by Country (2018-2023)
10.4 Middle East & Africa Neuroendocrine Carcinoma Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Detail
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Neuroendocrine Carcinoma Introduction
11.1.4 Pfizer Revenue in Neuroendocrine Carcinoma Business (2018-2023)
11.1.5 Pfizer Recent Development
11.2 Novartis
11.2.1 Novartis Company Detail
11.2.2 Novartis Business Overview
11.2.3 Novartis Neuroendocrine Carcinoma Introduction
11.2.4 Novartis Revenue in Neuroendocrine Carcinoma Business (2018-2023)
11.2.5 Novartis Recent Development
11.3 Chiasma
11.3.1 Chiasma Company Detail
11.3.2 Chiasma Business Overview
11.3.3 Chiasma Neuroendocrine Carcinoma Introduction
11.3.4 Chiasma Revenue in Neuroendocrine Carcinoma Business (2018-2023)
11.3.5 Chiasma Recent Development
11.4 Ipsen
11.4.1 Ipsen Company Detail
11.4.2 Ipsen Business Overview
11.4.3 Ipsen Neuroendocrine Carcinoma Introduction
11.4.4 Ipsen Revenue in Neuroendocrine Carcinoma Business (2018-2023)
11.4.5 Ipsen Recent Development
11.5 Abbvie
11.5.1 Abbvie Company Detail
11.5.2 Abbvie Business Overview
11.5.3 Abbvie Neuroendocrine Carcinoma Introduction
11.5.4 Abbvie Revenue in Neuroendocrine Carcinoma Business (2018-2023)
11.5.5 Abbvie Recent Development
11.6 Valeant
11.6.1 Valeant Company Detail
11.6.2 Valeant Business Overview
11.6.3 Valeant Neuroendocrine Carcinoma Introduction
11.6.4 Valeant Revenue in Neuroendocrine Carcinoma Business (2018-2023)
11.6.5 Valeant Recent Development
11.7 Jubilant
11.7.1 Jubilant Company Detail
11.7.2 Jubilant Business Overview
11.7.3 Jubilant Neuroendocrine Carcinoma Introduction
11.7.4 Jubilant Revenue in Neuroendocrine Carcinoma Business (2018-2023)
11.7.5 Jubilant Recent Development
11.8 Teva
11.8.1 Teva Company Detail
11.8.2 Teva Business Overview
11.8.3 Teva Neuroendocrine Carcinoma Introduction
11.8.4 Teva Revenue in Neuroendocrine Carcinoma Business (2018-2023)
11.8.5 Teva Recent Development
11.9 F.Hoffmann-La Roche
11.9.1 F.Hoffmann-La Roche Company Detail
11.9.2 F.Hoffmann-La Roche Business Overview
11.9.3 F.Hoffmann-La Roche Neuroendocrine Carcinoma Introduction
11.9.4 F.Hoffmann-La Roche Revenue in Neuroendocrine Carcinoma Business (2018-2023)
11.9.5 F.Hoffmann-La Roche Recent Development
11.10 Advanced Accelerator
11.10.1 Advanced Accelerator Company Detail
11.10.2 Advanced Accelerator Business Overview
11.10.3 Advanced Accelerator Neuroendocrine Carcinoma Introduction
11.10.4 Advanced Accelerator Revenue in Neuroendocrine Carcinoma Business (2018-2023)
11.10.5 Advanced Accelerator Recent Development
11.11 Mateon
11.11.1 Mateon Company Detail
11.11.2 Mateon Business Overview
11.11.3 Mateon Neuroendocrine Carcinoma Introduction
11.11.4 Mateon Revenue in Neuroendocrine Carcinoma Business (2018-2023)
11.11.5 Mateon Recent Development
11.12 Lexicon
11.12.1 Lexicon Company Detail
11.12.2 Lexicon Business Overview
11.12.3 Lexicon Neuroendocrine Carcinoma Introduction
11.12.4 Lexicon Revenue in Neuroendocrine Carcinoma Business (2018-2023)
11.12.5 Lexicon Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
